Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.21.2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2019     104,781,236          
Beginning balance at Dec. 31, 2019 $ 507,408   $ 105 $ 520,278   $ (1,618) $ (11,357)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Common stock issuance ESPP Plan (in shares)     34,330          
Common stock issuance ESPP Plan 796     796        
Issuance of restricted stock, net of forfeitures (in shares)     76,618          
Issuance of restricted stock, net of forfeitures (212)     (212)        
Issuance of common stock for stock options (in shares)     503,873          
Issuance of common stock for stock options 2,897     2,897        
Stock issuance fees and expenses (15)     (15)        
ESPP expense 194     194        
Stock-based compensation expense - options and restricted stock 1,991     1,991        
Gain (loss) on effective cash flow hedge (1,038)         (1,038)    
Net income (loss) (6,978)           (6,978)  
Ending balance (in shares) at Mar. 31, 2020     105,396,057          
Ending balance at Mar. 31, 2020 505,043   $ 105 525,929   (2,656) (18,335)  
Beginning balance (in shares) at Dec. 31, 2019     104,781,236          
Beginning balance at Dec. 31, 2019 507,408   $ 105 520,278   (1,618) (11,357)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net unrealized loss on marketable securities, net of tax (21)              
Loss on derivative reclassified from AOCI to earnings 2,661              
Net income (loss) (11,245)              
Ending balance (in shares) at Sep. 30, 2020     111,010,418          
Ending balance at Sep. 30, 2020 666,363   $ 111 688,832   22 (22,602)  
Beginning balance (in shares) at Mar. 31, 2020     105,396,057          
Beginning balance at Mar. 31, 2020 505,043   $ 105 525,929   (2,656) (18,335)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Common stock issuance ESPP Plan (in shares)     41,058          
Common stock issuance ESPP Plan 928     928        
Issuance of restricted stock, net of forfeitures (in shares)     24,786          
Issuance of restricted stock, net of forfeitures (824)     (824)        
Issuance of common stock for stock options (in shares)     183,443          
Issuance of common stock for stock options 2,014     2,014        
Issuance of common stock - public offering, net of underwriting discounts (in shares)     4,751,500          
Issuance of common stock - public offering, net of underwriting discounts 127,293   $ 5 127,288        
Stock issuance fees and expenses (209)     (209)        
ESPP expense 211     211        
Stock-based compensation expense - options and restricted stock 2,424     2,424        
Convertible note debt issuance costs (108)              
Equity component of convertible note issuance 30,912     30,912        
Tax liability related to convertible note issuance (9,330)     (9,330)        
Gain (loss) on effective cash flow hedge 38         38    
Loss on derivative reclassified from AOCI to earnings 2,661         2,661    
Net income (loss) (6,824)           (6,824)  
Ending balance (in shares) at Jun. 30, 2020     110,396,844          
Ending balance at Jun. 30, 2020 654,229   $ 110 679,235   43 (25,159)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Common stock issuance ESPP Plan (in shares)     29,853          
Common stock issuance ESPP Plan 808     808        
Issuance of restricted stock, net of forfeitures (in shares)     (1,124)          
Issuance of restricted stock, net of forfeitures (237)     (237)        
Issuance of common stock for stock options (in shares)     584,845          
Issuance of common stock for stock options 4,846   $ 1 4,845        
Stock issuance fees and expenses (29)     (29)        
ESPP expense 222     222        
Stock-based compensation expense - options and restricted stock 2,494     2,494        
Adjustment to tax liability related to convertible note issuance 1,524     1,524        
Convertible note debt issuance costs (30)              
Net unrealized loss on marketable securities, net of tax (21)         (21)    
Loss on derivative reclassified from AOCI to earnings 0              
Net income (loss) 2,557           2,557  
Ending balance (in shares) at Sep. 30, 2020     111,010,418          
Ending balance at Sep. 30, 2020 666,363   $ 111 688,832   22 (22,602)  
Beginning balance (in shares) at Dec. 31, 2020     112,075,474          
Beginning balance at Dec. 31, 2020 694,294 $ (22,575) $ 112 701,357 $ (23,271) 10 (7,185) $ 696
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Premiums paid for capped call confirmations (29,291)     (29,291)        
Common stock issuance ESPP Plan (in shares)     23,917          
Common stock issuance ESPP Plan 1,024     1,024        
Issuance of restricted stock, net of forfeitures (in shares)     83,220          
Issuance of restricted stock, net of forfeitures (614)     (614)        
Issuance of common stock for stock options (in shares)     260,167          
Issuance of common stock for stock options 2,239     2,239        
Issuance of common stock - public offering, net of underwriting discounts (in shares)     4,693,876          
Issuance of common stock - public offering, net of underwriting discounts 218,500   $ 5 218,495        
Stock issuance fees and expenses (242)     (242)        
ESPP expense 241     241        
Stock-based compensation expense - options and restricted stock 2,412     2,412        
Net unrealized loss on marketable securities, net of tax (160)         (160)    
Net income (loss) (22,114)           (22,114)  
Ending balance (in shares) at Mar. 31, 2021     117,136,654          
Ending balance at Mar. 31, 2021 843,714   $ 117 872,350   (150) (28,603)  
Beginning balance (in shares) at Dec. 31, 2020     112,075,474          
Beginning balance at Dec. 31, 2020 $ 694,294 $ (22,575) $ 112 701,357 $ (23,271) 10 (7,185) $ 696
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of common stock for stock options (in shares) 931,954              
Net unrealized loss on marketable securities, net of tax $ (400)              
Loss on derivative reclassified from AOCI to earnings 0              
Net income (loss) 33,412              
Ending balance (in shares) at Sep. 30, 2021     123,217,010          
Ending balance at Sep. 30, 2021 1,137,245   $ 123 1,110,590   (390) 26,922  
Beginning balance (in shares) at Mar. 31, 2021     117,136,654          
Beginning balance at Mar. 31, 2021 843,714   $ 117 872,350   (150) (28,603)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Common stock issuance ESPP Plan (in shares)     31,839          
Common stock issuance ESPP Plan 1,245     1,245        
Issuance of restricted stock, net of forfeitures (in shares)     146,392          
Issuance of restricted stock, net of forfeitures (163)     (163)        
Issuance of common stock for stock options (in shares)     354,310          
Issuance of common stock for stock options 4,430   $ 1 4,429        
Issuance of common stock - public offering, net of underwriting discounts (in shares)     4,444,445          
Issuance of common stock - public offering, net of underwriting discounts 189,863   $ 4 189,859        
Issuance of common stock for acquisition (in shares)     597,712          
Issuance of common stock for acquisition 29,175   $ 1 29,174        
Stock issuance fees and expenses (102)     (102)        
ESPP expense 298     298        
Stock-based compensation expense - options and restricted stock 4,208     4,208        
Net unrealized loss on marketable securities, net of tax (183)         (183)    
Net income (loss) 75,873           75,873  
Ending balance (in shares) at Jun. 30, 2021     122,711,352          
Ending balance at Jun. 30, 2021 1,148,358   $ 123 1,101,298   (333) 47,270  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Common stock issuance ESPP Plan (in shares)     27,210          
Common stock issuance ESPP Plan 1,020     1,020        
Issuance of restricted stock, net of forfeitures (in shares)     160,971          
Issuance of restricted stock, net of forfeitures (304)     (304)        
Issuance of common stock for stock options (in shares)     317,477          
Issuance of common stock for stock options 3,374     3,374        
Stock issuance fees and expenses (35)     (35)        
ESPP expense 236     236        
Stock-based compensation expense - options and restricted stock 5,001     5,001        
Net unrealized loss on marketable securities, net of tax (57)         (57)    
Loss on derivative reclassified from AOCI to earnings 0              
Net income (loss) (20,348)           (20,348)  
Ending balance (in shares) at Sep. 30, 2021     123,217,010          
Ending balance at Sep. 30, 2021 $ 1,137,245   $ 123 $ 1,110,590   $ (390) $ 26,922